Democratic Senators Angela Alsobrooks of Maryland and Ron Wyden of Oregon have formally raised severe concerns regarding emerging prediction market event contracts linked directly to clinical drug trials and Food and Drug Administration regulatory approvals. In an official letter sent to Department of Health and Human Services Secretary Robert F. Kennedy Jr., the two lawmakers inquired about specific risk mitigation actions that HHS has implemented to address the severe public health and financial dangers posed by these speculative derivative markets.
The senators explicitly warned that permitting individuals to bet on the outcomes of medical trials and pharmaceutical approvals significantly undermines the scientific research process. Citing warnings from healthcare professionals, the lawmakers emphasized that these clinical prediction markets establish perverse financial incentives for medical researchers, potentially distort patient decision-making regarding trial participation, and introduce heightened insider trading risks among regulators and scientists who maintain direct access to sensitive, nonpublic medical information.
To ensure proper regulatory oversight, the lawmakers requested that the Department of Health and Human Services produce all internal communications regarding staff involvement in prediction markets related to HHS-governed matters. Furthermore, they demanded complete records of all official correspondence between the department, active prediction market platforms, and the Commodity Futures Trading Commission—which regulates financial event contracts—alongside any internal risk analyses performed by HHS concerning medical trial betting.




